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Abstract: To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady
Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal
adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma,
and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min)
and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to
5 min. The impact of cold plasma on the reduction of viability was consistently dose-dependent;
however, the anti-cancer capability varied significantly between cell lines. While the lowest effective
dose varied from cell line to cell line, in each case an 80–99% reduction in viability was achievable
48 h after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for
treating a specific cancer cell type.
Keywords: cold atmospheric plasma; CAP; cancer therapy; dose-dependent; renal adenocarcinoma;
colorectal carcinoma; pancreatic adenocarcinoma; ovarian adenocarcinoma; esophageal adenocarcinoma
1. Introduction
Malignant solid tumors are characterized by high recurrence rates and low five-year survival
rates. Stage IV renal adenocarcinoma presents an extremely low five-year survival rate of 0–10% [1],
while the recurrence rate may be as high as 23% [2]. While the recurrence rate of colorectal carcinoma
is similar to that of renal adenocarcinoma at 19.4% to 21.6%, the five-year survival rate is significantly
higher at 88.6% to 89.4% [3]. Pancreatic ductal adenocarcinoma has an extremely low survival rate
of 10% to 28% [4] after one year due to a very high recurrence rate of 65.5% [5]. The resulting 5-year
survival rate is dismal at 6% in the United States and Europe [6]. Serous epithelial ovarian carcinoma
has a very low five-year survival rate of 42% for stage III and 26% for stage IV [7] with a 19% recurrence
rate [8]. Esophageal adenocarcinoma represents a similarly low five-year survival rate of 33% to
44% [9], depending on the treatment used, and can result in a recurrence rate as high as 43.2% [10].
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The unfortunately common recurrence of malignant solid tumors represents a unique opportunity
for cold atmospheric plasma (CAP) treatment. CAP is an emerging technology that uses ionized gas to
produce a plasma beam which has numerous applications in various fields, including dentistry, wound
healing, surface decontamination, viral inhibition, and cancer treatment [11–16]. CAP can be used to
treat the margins following tumor removal, and in doing so has the potential to remove residual cancer
cells and prevent recurrence. An important step to make this a reality is to determine the correct dose
of CAP to significantly reduce tumor cell viability. It has been reported that various cell lines react
differently to CAP treatment [17–20]. Yan et al. studied the reactive species consumption speed of
glioblastoma U87 and breast cancers MDA-MB-231 and MCF-7, and discovered that the cancer cells that
could absorb or eliminate the effective species in the media faster (glioblastoma) were more resistant to
plasma-activated media than both breast cancers [17]. Their results also demonstrate a wide range of
effects on cell viability depending on cell type and treatment time [20]. Naciri et al. also reported that
plasma sensitivity closely correlates with proliferation rates by measuring ATP levels of three cancer
cell types including Chinese hamster ovary cells, osteoblast, and colon adenocarcinoma [18]. By testing
eight cancerous cell lines, Ma et al. claimed that p53-deficient cancer cells are more sensitive to CAP
treatment due to the lack of p53-dependent cell cycle delay at G1 [19]. Therefore, the combinations of
power settings and treatment times are critical to establish the correct dosage of cell line-dependent
CAP treatment.
The mechanism of the anti-cancer capacity of CAP has been increasingly understood. Several theories
have been proposed, including a decrease of cell adhesion [21,22], interruption of the cell cycle [23–25],
induction of apoptosis [26–29], and DNA fragmentation [30]. However, it is not yet clear whether
CAP-generated reactive species are crucial for apoptosis and its associated DNA strand break or
whether plasma-induced direct DNA damage provokes cell cycle checkpoint signaling that leads to
apoptosis [31].
The Canady Cold Plasma Conversion Unit is unique in that it utilizes a high voltage transformer
to up-convert the voltage (1.5–50 kV), down-convert the frequency (<300 kHz), and down-convert the
power (<30 W) of the high-voltage output from an electrosurgical unit (U.S. Patent No. 9,999,462) [32].
We tested the Canady Helios Cold Plasma Device on a wide range of cell lines with different
combinations of power settings, treatment times, and gas flow rates. With optimal dosage for each
cancer type, this study provides a starting point for future animal studies and clinical trials.
2. Materials and Methods
2.1. Cold Plasma Device
All experiments were performed at the Jerome Canady Research Institute for Advanced Biological
and Technological Sciences, in Takoma Park, MD, USA. Cold atmospheric plasma (CAP) was generated
using a USMI SS-601 MCa high-frequency electrosurgical generator (USMI, Takoma Park, MD, USA)
integrated with a USMI Cold Plasma Conversion Unit and connected to a Canady Helios Cold Plasma
Scalpel. Helium flow was set to a constant 1 L/min and 20 P or 40 P or 3 L/min and power set to 40 P,
60 P, or 80 P. The plasma scalpel was placed so that the tip of the scalpel was 1.5 cm (at 1 L/min) or
2 cm (at 3 L/min) from the surface of the cell media and was not moved during treatment (Figure 1).
2.2. Optical Emission Spectroscopy
Optical emission spectroscopy with a range of 250–850 nm was performed on the CAP jet to
detect the reactive species. The spectrometer (EPP2000-HR) and detection probe were purchased from
Stellar Net Inc. (Tampa, FL, USA). The probe was placed 1.5 cm away from the tip of the scalpel,
perpendicular to the plasma beam. The integration time was set to 100 ms.
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Figure 1. Solid tumor treatment with cold atmospheric plasma. (A) Cells cultured in a 12-well plate, 
treated using a Canady Helios Plasma Scalpel (USMI, Takoma Park, MD, USA) at 3 L/min (B) Cold 
atmospheric plasma (CAP) generator device; USMI SS-601 MCa (top) connected to a USMI Cold 
Plasma Conversion Unit (bottom). 
2.3. Cell Culture 
BxPC-3 pancreatic adenocarcinoma and 769-P renal adenocarcinoma were purchased from 
ATCC (Manassas, VA, USA). OE33 esophageal adenocarcinoma was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). HCT-116 colorectal carcinoma and SK-OV-3 ovarian adenocarcinoma were 
generously donated by Professor Keidar’s lab at The George Washington University. All cell lines 
were maintained with the required culture media according to the supplier protocol. When cells 
reached approximately 80% confluence, they were seeded at a concentration of 5 × 103 or 105 cells/well 
into 96-well or 12-well plates (USA Scientific, Ocala, FL, USA), respectively, for cell viability assays. 
For BxPC-3, 1 × 104 cells were required for the 96-well assay. 
2.4. Cell Viability Assay 
Thiazolyl blue tetrazolium bromide (MTT) assay was performed on the cells 48 h after plasma 
treatment following the manufacturer’s protocol. Briefly, cells were incubated with MTT at a 
concentration of 0.5 mg/mL 48 h post treatment for 3 h in a 37 °C and 5% CO2 humidified incubator. 
Then, MTT solvent was added into each well to dissolve the formazan crystals. All the MTT assay 
reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). The absorbance of the dissolved 
compound was measured by BioTek Synergy HTX (Winooski, VT, USA) microplate reader at 570 nm. 
Cell viability assay data has been included as supplementary material. 
2.5. Statistics 
All viability assays were repeated at least 3 times with 2 replicates each. Data was plotted by 
Microsoft Excel 2016 as the mean ± standard error of the mean. A student t-test or a one-way analysis 
of variance (ANOVA) was used to check statistical significance where applicable. The differences 
were considered statistically significant for * p ≤ 0.05. 
  
Figure 1. Solid tumor treatment with cold atmospheric plasma. (A) Cells cultured in a 12-well
plate, treated using a Canady Helios Plasma Scalpel (USMI, Takoma Park, MD, USA) at 3 L/min
(B) Cold atmospheric plasma (CAP) generator device; USMI SS-601 MCa (top) connected to a USMI
Cold Plasma Conversion Unit (bottom).
2.3. Cell Culture
BxPC-3 pancreatic adenocarcinoma and 769-P renal adenocarcinoma were purchased from ATCC
(Manassas, VA, USA). OE33 esophageal adenocarcinoma was purchased from Sigma-Aldrich (St. Louis,
MO, USA). HCT-116 colorectal carcinoma and SK-OV-3 ovarian adenocarcinoma were generously
donated by Professor Keidar’s lab at The George Washington University. All cell lines were maintained
with the required culture media according to the supplier protocol. When cells reached approximately
80% confluence, they were seeded at a concentration of 5 × 103 or 105 cells/well into 96-well or 12-well
plates (USA Scientific, Ocala, FL, USA), respectively, for cell viability assays. For BxPC-3, 1 × 104 cells
were required for the 96-well assay.
2.4. Cell Viability Assay
Thiazolyl blue tetrazolium bromide (MTT) assay was performed on the cells 48 h after plasma
treatment following the manufacturer’s protocol. Briefly, cells were incubated with MTT at a
concentration of 0.5 mg/mL 48 h post treatment for 3 h in a 37 ◦C and 5% CO2 humidified incubator.
Then, MTT solvent was added into each well to dissolve the formazan crystals. All the MTT assay
reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). The absorbance of the dissolved
compound was measured by BioTek Synergy HTX (Winooski, VT, USA) microplate reader at 570 nm.
Cell viability assay data has been included as supplementary material.
2.5. Statistics
All viability assays were repeated at least 3 ti es with 2 replicates each. Data was plotted by
Microsoft Excel 2016 as the mean ± standard error of the mean. A student t-test or a one-way analysis
of variance (ANOVA) was used to check statistical significance where applicable. The differences were
considered statistically significant for * p ≤ 0.05.
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3. Results
Reduction of Cell Viability by CAP in Malignant Solid Tumor Cell Lines
To determine the effective plasma dose required to significantly reduce cell viability two flow
rates were chosen; 1 L/min and 3 L/min of helium. Helium was used as the carrier gas because the
breakdown voltage of helium is significantly lower than nitrogen [33]. In addition, the low excitation
energy level of argon metastables (11.7 and 11.5 eV) in comparison with helium (20.6 and 19.8 eV) does
not allow an efficient Penning ionization to sustain the discharge [34]. Based on initial testing, 1–5 min
with 40–80 power, and 30–120 s with 20–40 power, were chosen as an effective range for 3 L/min
and 1 L/min, respectively. The power settings of 20 P, 40 P, 60 P, and 80 P used in this study are 5 W,
8 W, 11 W, and 15.7 W at 3 L/min. At 1 L/min of 20 P and 40 P, the power settings are 5 W and 6 W
respectively. The detailed power measurement of our CAP device was conducted and reported in
another paper which is currently under review [35]. The spectrum of the CAP jet is shown in Figure 2.
The most intense peaks and bands of plasma between 250 and 850 nm were referenced [36] and
labeled in the figure. The main species observed were: OH (A2∑+–X2Π+) at 309 nm, N2 (C3Πu–B3Πg)
second positive system (SPS) at 337 and 357 nm; N2+ (B2∑u+–X2∑g+) first negative system (FNS) at
391 and 427 nm; He at 667 nm; and OI at 777 nm. The cold plasma jet is a complicated environment
that combines the comprehensive effect of a variety of ions and neutrals. These reactive oxygen and
nitrogen species are playing essential roles in cellular responses to the CAP treatment [37,38].
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Figure 2. The spectrum of CAP generated by the USMI Cold Plasma Conversion Unit and Canady 
Helios Cold Plasma Scalpel. Data shown are in the optical emission spectroscopy within a range of 
250–850 nm, measured 1.5 cm from the tip of the scalpel. Main species include OH (309 nm), N2 (337 
and 357 nm), N2+ (391 and 427 nm), He (667 nm), and O (777 nm). 
MTT assays were used to determine the dose of CAP needed to significantly reduce cell viability. 
MTT assays were performed on CAP-treated cancer cell lines 48 h post treatment. The viability of the 
treated cells was normalized to an untreated (control) group. The viability of 769-P renal 
adenocarcinoma cells was dose-dependent and significantly reduced at all time and power 
combinations tested (Figure 3). Helium flow alone (0 W) did not significantly impact cell viability 
(Figure 3A). At the highest doses, using 3 L/min, viability was reduced to 4.9% (p < 0.001) while 
viability at 20 P for 120 s was <1% (p < 0.001) for 1 L/min. Increasing the power to 40 P did not result 
in a further reduction (p = 0.65) (Figure 3B). CAP was equally as effective in reducing viability in 
HCT-116 colorectal carcinoma cells. At 3 L/min, viability was 76% at 40 P for 1 min (p < 0.01) and this 
decreased to 3.6% at the highest dose of 80 P for 5 min (p < 0.001) (Figure 4A). The decrease in viability 
when using 1 L/min required a lower dose. Initially, at 20 P for 30 s and 60 s, viability was reduced 
to 27% (p < 0.001) and 21% (p < 0.01), respectively (Figure 4B). However, beginning at 20 P for 90 s 
Figure 2. The spectrum of CAP generated by the USMI Cold Plasma Conversion Unit and Canady
Helios Cold Plasma Scalpel. Data shown are in the optical emission spectroscopy within a range of
250–850 nm, measured 1.5 cm from the tip of the scalpel. Main species include OH (309 nm), N2
(337 and 357 nm), N2+ (391 and 427 nm), He (667 nm), and O (777 nm).
a says were used to determin the dose of CAP needed to significantly reduce cell
viability. MTT assays were perform d on CAP-treated cancer cell lines 48 h post treatment.
The viability of the treated c lls was normaliz to a untreated (control) group. The viability of
769-P renal adenocarcinoma cell was dose-depe ent a d significantly r uced at all time and
i ti t t ( i ). li fl l ( ) i t i ifi tl i t ll i ilit
( i ). t t i t , i L i , i ilit t . ( . ) il
i ilit t s . in. Increasing t e t i t lt
i i . i . ll i i i i ili i
l l carci o a cells. At 3 L/min, viability was 76% at 40 P for 1 min (p < 0.01) and
this decreased to 3.6% at the highest dose o 80 P for 5 min (p < 0.001) (Figure 4A). The decrease in
viability when using 1 L/min required a lower dose. Initially, at 20 P for 3 and 60 s, vi bility was
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reduced to 27% (p < 0.001) and 21% (p < 0.01), respectively (Figure 4B). However, beginning at 20 P
for 90 s viability was reduced to 5.0% (p < 0.001) which only slightly decreased with a higher dose,
with the highest dose resulting in 2.6% viability (p < 0.001). CAP also had a clear dose-dependent
effect on the reduction of viability in the ovarian adenocarcinoma cell line; SK-OV-3. At the lowest
dose, using 3 L/min, viability was only reduced to 87% (p < 0.001), which decreased to 17% (p < 0.001)
at 80 P for 5 min (Figure 5A). Similar results were found with a lower flow rate (Figure 5B). 20 P for
30 s resulted in 77% viability (p < 0.001), which decreased to 4% viability (p < 0.0001) at 40 P for 120 s.
BxPC-3 (pancreatic adenocarcinoma) required a higher dose to effectively reduce viability (Figure 6A).
At 60 P for 5 min and 80 P for 5 min, viability was reduced to 14% (p < 0.0001) and 4% (p < 0.0001),
respectively. The low flow rate treatment showed a similar pattern requiring a higher dose to reduce
viability. At 40 P for 90 s and 40 P for 120 s the viability was reduced to 5% (p < 0.0001) and 1%
(p < 0.0001), respectively (Figure 6B). The esophageal adenocarcinoma cell line, OE33, also required a
higher dose to decrease viability below 20%. Using the high flow rate at 80 P for 5 min viability was
reduced to 16% (p < 0.001) (Figure 7A). At 1 L/min and 40 P for 120 s viability was reduced to 15%
(p < 0.0001) (Figure 7B). Taken together, this data demonstrates that CAP reduced cell viability in a
time- and power-dependent manner in all cell lines tested.
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Figure 3. The reduction of viability of 769-P (renal adenocarcinoma) following CAP treatment. (A) 
769-P cells were cultured in 12-well plates and treated with CAP at 3 L/min; (B) 769-P cells were 
cultured in 96-well plates and treated with CAP at 1 L/min. CAP treatment of 769-P significantly 
reduces viability at all doses tested, at both 3 L/min and 1 L/min. * p ≤ 0.05. 
i . reduction of viability of 769-P (renal adenocarcinoma) following CAP treatmen . (A) 769-P
cells w re cultured in 12-well plates and treated with CAP a 3 L/min; (B) 769-P cells were cu tured in
96-well plates and treated with CAP at 1 L/min. CAP treat ent of 769-P significantly reduces viabilit
at all doses tes ed, at both 3 L/min and 1 L/min. * p ≤ 0.05.
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Figure 5. The reduction of the viability of SK-OV-3 (ovarian adenocarcinoma) following CAP 
treatment. (top) SK-OV-3 cells were cultured in 12-well plates and treated with CAP at 3 L/min; 
(bottom) SK-OV-3 cells were cultured in 96-well plates and treated with CAP at 1 L/min. CAP 
treatment of SK-OV-3 significantly reduces viability at nearly all doses tested using 3 L/min (Figure 
4A) and at all doses using 1 L/min flow rate (Figure 4B). * p ≤ 0.05. 
Figure 4. The reduction of the viability of HCT-116 (colorectal carcinoma) following CAP treatment.
(A) HCT-116 cells were cultured in 12-well plates and treated with CAP at 3 L/min; (B) HCT-116
cells were cultured in 96-well plates and treated with CAP at 1 L/min. CAP treatment of HCT-116
significantly reduces viability at all doses tested, at both 3 L/min and 1 L/min. * p ≤ 0.05.
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Figure 5. The reduction of the viability of SK-OV-3 (ovarian adenocarcinoma) following CAP treatment.
(top) SK-OV-3 cells were cultured in 12-well plates and treated with CAP at 3 L/min; (bottom) SK-OV-3
cells were cultured in 96-well plates and treated with CAP at 1 L/min. CAP treatment of SK-OV-3
significantly reduces viability at nearly all doses tested using 3 L/min (Figure 4A) and at all doses
using 1 L/min flow rate (Figure 4B). * p ≤ 0.05.
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Figure 7. The reduction of the viability of OE33 (esophageal adenocarcinoma) following CAP 
treatment. (top) OE33 cells were cultured in 12-well plates and treated with CAP at 3 L/min; (bottom) 
OE33 cells were cultured in 96-well plates and treated with CAP at 1 L/min. CAP treatment of OE33 
significantly reduces viability at all doses tested, at both 3 L/min and 1 L/min. * p ≤ 0.05. 
4. Discussion 
This study is the first effort to describe the dose-dependent reduction of viability, as a 
combination of treatment time and power settings, on multiple malignant solid tumor cell lines using 
the USMI Cold Plasma Conversion Unit and Canady Helios Cold Plasma Scalpel. This CAP does not 
induce any damage on normal tissue, which is described in detail in a separate paper [39]. CAP 
treatment consistently resulted in a dose-dependent reduction in viability on all solid tumor cell lines 
Figure 6. The reduction of the viability of BxPC-3 (pancreatic adenocarcinoma) following CAP
treatment. (A) BxPC-3 cells were cultured in 12-well plates and treated with CAP at 3 L/min; (B) BxPC-3
cells were cultured in 96-well plates and treated with CAP at 1 L/min. CAP treatment of BxPC-3
significantly reduces viability at all doses tested using 3 L/min (Figure 4A) and at nearly all doses
using 1 L/min flow rate (Figure 4B). * p ≤ 0.05.
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Figure 7. The reduction of the viability of OE33 (esophageal adenocarcinoma) following CAP treatment.
(top) OE33 cells were cultured in 12-well plates and treated with CAP at 3 L/min; (bottom) OE33 cells
were cultured in 96-well plates and treated with CAP at 1 L/min. CAP treatment of OE33 significantly
reduces viability at all doses tested, at both 3 L/min and 1 L/min. * p ≤ 0.05.
4. i u i n
This study is the first effort to describe the dose-dependent r duction of viability, as a combination
of treatment time and power settings, on multiple malignant solid tumor cell lines using th USMI
Cold Plasma Conversion Unit and Canady Helios Cold Plasma Scalpel. This CAP does not induce
Plasma 2018, 1 184
any damage on normal tissue, which is described in detail in a separate paper [39]. CAP treatment
consistently resulted in a dose-dependent reduction in viability on all solid tumor cell lines tested.
While the lowest effective dose varied from cell line to cell line, in each case an 80–99% reduction
in viability was achievable 48 h after CAP treatment. 769-P and HCT-116 required a lower dose of
plasma while SK-OV-3, BxPC-3, and OE33 required a relatively higher dose. In all cell lines tested,
helium treatment alone (0 P) showed no decrease in viability, indicating that the observed effects
are due to CAP. While in several of the cell lines 1 L/min flow rate resulted in a lower viability at a
lower dose, this cannot be directly compared with the 3 L/min results. This is because the treatment
conditions, including well size, beam length, media volume, and cell number, are different between
these two assays, and Yan et al. demonstrated that those conditions can alter the effect of CAP on
cell viability [17,20]. Xu et al. have suggested a formula to compare plasma dose among treatment
conditions within one cell type and this may be necessary to compare future results [40].
Ma et al. demonstrated that the effectiveness of non-thermal plasma treatment was partially
dependent on p53 expression [19]. The viability of cancer cells lacking p53 was significantly reduced
by non-thermal plasma treatment while p53+ cells were less affected. It is thought that this is due
to the role of p53 in protecting the cell from reactive oxygen species [41]. However, based on the
established literature, the cell lines tested here, except for SK-OV-3, have been shown to be positive
for p53 (Table 1). Ma et al. also used HCT-116 and surprisingly found only a slight reduction in
viability whereas we found that viability was reduced to as low as 3.6% (Figure 4A). This is likely due
to differences in plasma generation, flow rate, and assay timing. The cell lines tested here also include
both wild-type (WT) and mutant p53 (Table 1). Despite positive p53 expression, or status, the viability
of these cell types was significantly affected by CAP treatment. However, the cell lines with wild-type
p53 (769-P/Figure 3, HCT-116/Figure 4) tended to require a lower dose of CAP to reduce viability
compared to those with mutant p53 (BxPC-3/Figure 6, OE33/Figure 7).
Table 1. Status and expression of p53 in all cell types tested; wild-type (WT) and mutant (MUT).
Cell Name Cell Type p53 Status P53 Expression Reference
769-P Renal adenocarcinoma WT Positive [42–45]
HCT-116 Colorectal carcinoma WT Positive [19,46]
SK-OV-3 Ovarian adenocarcinoma MUT/NULL Negative [45–48]
BxPC-3 Pancreatic adenocarcinoma MUT Positive [49–51]
OE33 Esophageal adenocarcinoma MUT Positive [45,52]
Further experiments will investigate the effect of CAP on additional cancerous cell lines as well
as normal tissues to demonstrate the safety of our cold plasma device. The potential of CAP and
chemotherapy combined therapies has been reported repeatedly [53–55]. For cell lines that require
a higher dose of CAP to effectively reduce viability, that dose may be reduced with the addition
of chemotherapy drugs. Lee et al. demonstrated that CAP can overcome drug resistance in breast
cancer [56] and a similar combination therapy may also further reduce the viability of our cell lines.
Future experiments will also include preclinical murine models to determine the efficacy of CAP
on tumor reduction and prevention of recurrence. Tumors would be treated directly with CAP and
tumor size and survival would be measured. To determine the effect of CAP in preventing tumor
recurrence; the tumor would be surgically removed and the resulting margins would be treated with
CAP. These experiments would match the approach taken in a surgical setting and could lead to
improved patient outcomes.
5. Conclusions
This study is the first effort to describe the dose-dependent reduction of viability on multiple
malignant solid tumor cell lines using the USMI Cold Plasma Conversion Unit and Canady Helios
Cold Plasma Scalpel. The impact of cold plasma on the reduction of viability was consistently
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dose-dependent and, in each case, an 80–99% reduction in viability was achievable 48 h after CAP
treatment. These data demonstrate that the dose required to reduce viability was variable between
cell lines; therefore, it is important to select the appropriate CAP dose necessary for treating a specific
cancer cell type. This study will provide a cell line-specific dose estimation for future preclinical and
clinical studies.
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